These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31331783)

  • 1. The clinical correlation and predictive value of electrophysiological variables on clinical response to clozapine in patients with treatment-resistant schizophrenia.
    Gica S; Buyukavsar A; Poyraz BC; Gulec H
    Schizophr Res; 2019 Sep; 211():108-110. PubMed ID: 31331783
    [No Abstract]   [Full Text] [Related]  

  • 2. Interactive ERP recording increases the amplitude of the endogenous P300 peak in schizophrenia.
    Price GW
    Schizophr Res; 2000 Feb; 41(3):463-72. PubMed ID: 10728723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of clozapine on auditory event-related potentials in schizophrenia.
    Umbricht D; Javitt D; Novak G; Bates J; Pollack S; Lieberman J; Kane J
    Biol Psychiatry; 1998 Oct; 44(8):716-25. PubMed ID: 9798075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EEG coherence following acute and chronic clozapine in treatment-resistant schizophrenics.
    Knott VJ; LaBelle A; Jones B; Mahoney C
    Exp Clin Psychopharmacol; 2002 Nov; 10(4):435-44. PubMed ID: 12498341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topographic analysis of EEG photic driving in patients with schizophrenia following clozapine treatment.
    Jin Y; Potkin SG; Sandman CA; Bunney WE
    Clin Electroencephalogr; 1998 Apr; 29(2):73-8. PubMed ID: 9571294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P300 and symptom improvement in schizophrenia.
    Gallinat J; Riedel M; Juckel G; Sokullu S; Frodl T; Moukhtieva R; Mavrogiorgou P; Nisslé S; Müller N; Danker-Hopfe H; Hegerl U
    Psychopharmacology (Berl); 2001 Oct; 158(1):55-65. PubMed ID: 11685384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P300 alterations in schizophrenic patients experiencing auditory hallucinations.
    Papageorgiou C; Oulis P; Vasios C; Kontopantelis E; Uzunoglu N; Rabavilas A; Christodoulou GN
    Eur Neuropsychopharmacol; 2004 May; 14(3):227-36. PubMed ID: 15056482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of clozapine on awareness of illness and cognition in schizophrenia.
    Pallanti S; Quercioli L; Pazzagli A
    Psychiatry Res; 1999 Jun; 86(3):239-49. PubMed ID: 10482343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of the long term treatment with clozapine. Clinical and electroencephalographic study.
    Zapletálek M; Hanus H; Kucera V; Kuba M
    Act Nerv Super (Praha); 1989 Apr; 31(1):36-7. PubMed ID: 2571221
    [No Abstract]   [Full Text] [Related]  

  • 10. Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T/C) and increment of N100 amplitude in schizophrenics treated with clozapine.
    Yu YW; Tsai SJ; Yang KH; Lin CH; Chen MC; Hong CJ
    Neuropsychobiology; 2001; 43(2):79-82. PubMed ID: 11174050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study to determine whether machine learning methodologies using pre-treatment electroencephalography can predict the symptomatic response to clozapine therapy.
    Khodayari-Rostamabad A; Hasey GM; Maccrimmon DJ; Reilly JP; de Bruin H
    Clin Neurophysiol; 2010 Dec; 121(12):1998-2006. PubMed ID: 21035741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clozapine improves working memory updating in schizophrenia.
    Galletly CA; Clark CR; McFarlane AC
    Eur Neuropsychopharmacol; 2005 Dec; 15(6):601-8. PubMed ID: 15905072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clozapine for Treatment-Resistant Schizophrenia.
    Manu P; Grudnikoff E
    Am J Ther; 2016; 23(5):e1133-4. PubMed ID: 27603450
    [No Abstract]   [Full Text] [Related]  

  • 14. Clozapine, but not typical antipsychotics, correct P50 suppression deficit in patients with schizophrenia.
    Becker J; Gomes I; Ghisolfi ES; Schuch A; Ramos FL; Ehlers JA; Nora DB; Lara DR; da Costa JC
    Clin Neurophysiol; 2004 Feb; 115(2):396-401. PubMed ID: 14744582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of the P300 and P50 waveforms in schizophrenia.
    Bramon E; Rabe-Hesketh S; Sham P; Murray RM; Frangou S
    Schizophr Res; 2004 Oct; 70(2-3):315-29. PubMed ID: 15329307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of theta-rhythm transcranial alternating current stimulation (4.5 Hz-tACS) in patients with clozapine-resistant negative symptoms of schizophrenia: a case series.
    Kallel L; Mondino M; Brunelin J
    J Neural Transm (Vienna); 2016 Oct; 123(10):1213-7. PubMed ID: 27194229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clozapine-induced QEEG changes correlate with clinical response in schizophrenic patients: a prospective, longitudinal study.
    Gross A; Joutsiniemi SL; Rimon R; Appelberg B
    Pharmacopsychiatry; 2004 May; 37(3):119-22. PubMed ID: 15138895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What do ERPs and ERFs reveal about the effect of antipsychotic treatment on cognition in schizophrenia?
    Korostenskaja M; Kähkönen S
    Curr Pharm Des; 2009; 15(22):2573-93. PubMed ID: 19689329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. State and trait markers of emotionally charged visual event-related potentials (P300) in drug-naïve schizophrenia.
    Mori K; Morita K; Shoji Y; Matsuoka T; Fujiki R; Uchimura N
    Psychiatry Clin Neurosci; 2012 Jun; 66(4):261-9. PubMed ID: 22624730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential clinical, structural and P300 parameters in schizophrenia patients resistant to conventional neuroleptics.
    Molina V; Reig S; Sanz J; Palomo T; Benito C; Sarramea F; Pascau J; Sánchez J; Martín-Loeches M; Muñoz F; Desco M
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):257-66. PubMed ID: 17900778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.